UK markets close in 39 minutes
  • FTSE 100

    7,517.08
    -18.98 (-0.25%)
     
  • FTSE 250

    20,099.05
    -237.36 (-1.17%)
     
  • AIM

    926.14
    -5.40 (-0.58%)
     
  • GBP/EUR

    1.1844
    -0.0045 (-0.38%)
     
  • GBP/USD

    1.2053
    -0.0042 (-0.34%)
     
  • BTC-GBP

    19,413.66
    -387.12 (-1.96%)
     
  • CMC Crypto 200

    555.08
    -17.74 (-3.10%)
     
  • S&P 500

    4,268.05
    -37.15 (-0.86%)
     
  • DOW

    33,939.66
    -212.35 (-0.62%)
     
  • CRUDE OIL

    88.30
    +1.77 (+2.05%)
     
  • GOLD FUTURES

    1,781.10
    -8.60 (-0.48%)
     
  • NIKKEI 225

    29,222.77
    +353.86 (+1.23%)
     
  • HANG SENG

    19,922.45
    +91.93 (+0.46%)
     
  • DAX

    13,661.18
    -248.94 (-1.79%)
     
  • CAC 40

    6,533.14
    -59.44 (-0.90%)
     

Multiple insiders bought e-therapeutics plc (LON:ETX) stock earlier this year, a positive sign for shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of e-therapeutics plc (LON:ETX), that sends out a positive message to the company's shareholders.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for e-therapeutics

e-therapeutics Insider Transactions Over The Last Year

The CEO & Director Ahmad Mortazavi made the biggest insider purchase in the last 12 months. That single transaction was for UK£100k worth of shares at a price of UK£0.36 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of UK£0.43. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

In the last twelve months e-therapeutics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

e-therapeutics Insiders Bought Stock Recently

Over the last quarter, e-therapeutics insiders have spent a meaningful amount on shares. Specifically, CEO & Director Ahmad Mortazavi bought UK£100k worth of shares in that time, and we didn't record any sales whatsoever. This could be interpreted as suggesting a positive outlook.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. e-therapeutics insiders own about UK£105m worth of shares (which is 48% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The e-therapeutics Insider Transactions Indicate?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about e-therapeutics. Nice! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - e-therapeutics has 3 warning signs we think you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting